Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3 Thoracic 2 CNS 2 Tumor-Agnostic 1 Lymphoid 1 Genitourinary 1

Conditions

Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1

Interventions

Rituximab 702 Cyclophosphamide 645 Vincristine 353 Doxorubicin 309 Etoposide 305 Cytarabine 271 Filgrastim 250 Prednisone 249 Methotrexate 241 fludarabine phosphate 231 Dexamethasone 209 fludarabine 184 Peripheral Blood Stem Cell Transplantation 166 Radiotherapy 161 Granulocyte Colony-Stimulating Factor 145 Lenalidomide 144 Bendamustine Hydrochloride 142 Bortezomib 127 Melphalan 126 ibrutinib 111 Busulfan 111 Mycophenolic Acid 108 Whole-Body Irradiation 107 Tacrolimus 96 Cyclosporine 87 Gemcitabine 82 Ifosfamide 80 Calcium Dobesilate 80 Alemtuzumab 80 Leucovorin 78

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × vistusertib × Lymphoid × Clear all

NCT02752204 2020-11-05

TORCH

University of Birmingham

Phase 2 Completed

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡